JP6002149B2 - ポリマー−スニチニブコンジュゲート - Google Patents

ポリマー−スニチニブコンジュゲート Download PDF

Info

Publication number
JP6002149B2
JP6002149B2 JP2013546460A JP2013546460A JP6002149B2 JP 6002149 B2 JP6002149 B2 JP 6002149B2 JP 2013546460 A JP2013546460 A JP 2013546460A JP 2013546460 A JP2013546460 A JP 2013546460A JP 6002149 B2 JP6002149 B2 JP 6002149B2
Authority
JP
Japan
Prior art keywords
compound
sunitinib
poly
daltons
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013546460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503548A (ja
JP2014503548A5 (https=
Inventor
ショーン エム． カルバートソン，
ショーン エム． カルバートソン，
アントニ コズロウスキ，
アントニ コズロウスキ，
トニー ドリュー ビンソン，
トニー ドリュー ビンソン，
Original Assignee
ネクター セラピューティクス
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス, ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2014503548A publication Critical patent/JP2014503548A/ja
Publication of JP2014503548A5 publication Critical patent/JP2014503548A5/ja
Application granted granted Critical
Publication of JP6002149B2 publication Critical patent/JP6002149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013546460A 2010-12-23 2011-12-23 ポリマー−スニチニブコンジュゲート Active JP6002149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426919P 2010-12-23 2010-12-23
US61/426,919 2010-12-23
PCT/US2011/067259 WO2012088529A1 (en) 2010-12-23 2011-12-23 Polymer-sunitinib conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016136547A Division JP2016185978A (ja) 2010-12-23 2016-07-11 ポリマー−スニチニブコンジュゲート

Publications (3)

Publication Number Publication Date
JP2014503548A JP2014503548A (ja) 2014-02-13
JP2014503548A5 JP2014503548A5 (https=) 2014-12-25
JP6002149B2 true JP6002149B2 (ja) 2016-10-05

Family

ID=45529206

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013546460A Active JP6002149B2 (ja) 2010-12-23 2011-12-23 ポリマー−スニチニブコンジュゲート
JP2016136547A Withdrawn JP2016185978A (ja) 2010-12-23 2016-07-11 ポリマー−スニチニブコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016136547A Withdrawn JP2016185978A (ja) 2010-12-23 2016-07-11 ポリマー−スニチニブコンジュゲート

Country Status (4)

Country Link
US (3) US9827326B2 (https=)
EP (1) EP2654799B1 (https=)
JP (2) JP6002149B2 (https=)
WO (1) WO2012088529A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111582B2 (en) * 2019-03-08 2021-09-07 Applied Materials, Inc. Porous showerhead for a processing chamber

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943605B2 (en) 2010-12-23 2018-04-17 Nektar Therapeutics Polymer-semaxanib moiety conjugates
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
JP6542799B2 (ja) * 2014-12-04 2019-07-10 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 新規ｐｅｇ誘導体
CN104610231B (zh) * 2015-01-28 2016-08-17 广州葳澜生物科技有限公司 一种舒尼替尼前药
US9808531B2 (en) 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
CA3056923A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP1255536B1 (en) 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
CA2407799A1 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
US7053144B1 (en) 2002-06-13 2006-05-30 Cmi Rubber Company, Inc. High density rubber compounds
WO2004084949A2 (en) 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
WO2005107815A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
KR101513732B1 (ko) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
AU2008331868B2 (en) 2007-11-28 2015-02-12 Nektar Therapeutics Oligomer-tricyclic conjugates
JP5704925B2 (ja) 2008-02-08 2015-04-22 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−カンナビノイドコンジュゲート
AU2009234322B2 (en) 2008-04-11 2014-12-04 Nektar Therapeutics Oligomer-aryloxy-substituted propanamine conjugates
EP2303288A4 (en) * 2008-05-22 2015-04-22 Univ Ramot CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE
KR101671537B1 (ko) * 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
US20120052041A1 (en) 2009-02-04 2012-03-01 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
US20120094998A1 (en) * 2009-04-17 2012-04-19 Nektar Therapeutics Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates
US8816077B2 (en) * 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111582B2 (en) * 2019-03-08 2021-09-07 Applied Materials, Inc. Porous showerhead for a processing chamber

Also Published As

Publication number Publication date
US10682418B2 (en) 2020-06-16
WO2012088529A1 (en) 2012-06-28
US9827326B2 (en) 2017-11-28
JP2014503548A (ja) 2014-02-13
US20180043028A1 (en) 2018-02-15
EP2654799B1 (en) 2017-11-08
US20130331425A1 (en) 2013-12-12
US20200261587A1 (en) 2020-08-20
US11419943B2 (en) 2022-08-23
JP2016185978A (ja) 2016-10-27
EP2654799A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
JP6009457B2 (ja) ポリマー−デスエチルスニチニブコンジュゲート
JP6002149B2 (ja) ポリマー−スニチニブコンジュゲート
CA2947895C (en) Nanoparticle drug conjugates
US11007270B2 (en) Polymer-semaxanib moiety conjugates
US9095622B2 (en) Oligomer-protein tyrosine kinase inhibitor conjugates
US20120094998A1 (en) Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates
WO2010120388A1 (en) Oligomer-protein tyrosine kinase inhibitor conjugates
JP5693967B2 (ja) オリゴマー−ジアリールピペラジンコンジュゲート
Kozlowski et al. Polymer-des-ethyl sunitinib conjugates
JP5792175B2 (ja) オリゴマー−カルシミメティクスコンジュゲートおよび関連化合物
JP2012502906A (ja) オリゴマー−プロテアーゼ阻害剤コンジュゲート
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160902

R150 Certificate of patent or registration of utility model

Ref document number: 6002149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250